Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review.

IF 1.8 Q3 ONCOLOGY
Radiation Oncology Journal Pub Date : 2021-06-01 Epub Date: 2021-06-25 DOI:10.3857/roj.2021.00108
Peiman Haddad, Reza Ghalehtaki, Arefeh Saeedian, Farshid Farhan, Mohammad Babaei, Mahdi Aghili
{"title":"Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review.","authors":"Peiman Haddad,&nbsp;Reza Ghalehtaki,&nbsp;Arefeh Saeedian,&nbsp;Farshid Farhan,&nbsp;Mohammad Babaei,&nbsp;Mahdi Aghili","doi":"10.3857/roj.2021.00108","DOIUrl":null,"url":null,"abstract":"<p><p>Rectal cancer is one of the most prevalent cancers in the world. In many countries, the current standard of care is long-course chemoradiation (CRT), followed by total mesorectal excision. Some efforts have been made by intensifying radiation or chemotherapy components of the neoadjuvant therapy to further decrease the local recurrence and augment surgery's feasibility and improve the oncological outcomes. This paper reviews recent intensified neoadjuvant interventions in locally advanced rectal cancer (LARC) in terms of efficacy and treatment-related toxicity. Many maneuvers have been made so far to improve the oncological outcomes of rectal cancer with intensified neoadjuvant long-course CRT. Some of these approaches seem compelling and deserve further study, while some have just increased the treatment-related toxicities without evident benefits. Those endeavors with greater pathological complete response than the standard of care may make us await the long-term results on survival rates and chronic treatment-related toxicity. After introduction of neoadjuvant CRT for LARC there have been many efforts to improve its outcomes. Here, this study gathered most of these efforts that intensified the neoadjuvant therapy with some being promising and some being futile.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/62/roj-2021-00108.PMC8497854.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3857/roj.2021.00108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Rectal cancer is one of the most prevalent cancers in the world. In many countries, the current standard of care is long-course chemoradiation (CRT), followed by total mesorectal excision. Some efforts have been made by intensifying radiation or chemotherapy components of the neoadjuvant therapy to further decrease the local recurrence and augment surgery's feasibility and improve the oncological outcomes. This paper reviews recent intensified neoadjuvant interventions in locally advanced rectal cancer (LARC) in terms of efficacy and treatment-related toxicity. Many maneuvers have been made so far to improve the oncological outcomes of rectal cancer with intensified neoadjuvant long-course CRT. Some of these approaches seem compelling and deserve further study, while some have just increased the treatment-related toxicities without evident benefits. Those endeavors with greater pathological complete response than the standard of care may make us await the long-term results on survival rates and chronic treatment-related toxicity. After introduction of neoadjuvant CRT for LARC there have been many efforts to improve its outcomes. Here, this study gathered most of these efforts that intensified the neoadjuvant therapy with some being promising and some being futile.

局部晚期直肠癌长期放化疗强化的当前方法综述。
直肠癌是世界上最常见的癌症之一。在许多国家,目前的治疗标准是长期放化疗(CRT),然后是全肠系膜切除术。为了进一步减少局部复发,提高手术的可行性,改善肿瘤预后,在新辅助治疗中加强放疗或化疗成分已做了一些努力。本文综述了近年来局部晚期直肠癌(LARC)强化新辅助干预的疗效和治疗相关毒性。为了提高直肠癌的肿瘤预后,强化新辅助长疗程CRT已经进行了许多操作。其中一些方法似乎很有说服力,值得进一步研究,而有些方法只是增加了治疗相关的毒性,没有明显的益处。那些比标准治疗有更大病理完全反应的努力可能会让我们等待生存率和慢性治疗相关毒性的长期结果。在LARC引入新辅助CRT后,已经有许多努力来改善其结果。在这里,本研究收集了大多数强化新辅助治疗的努力,有些是有希望的,有些是徒劳的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
24
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信